Startup Scout 9 Aug 2019 This Biotech Cleans up Drugs from Sewage Using Enzymes We’re visiting Uppsala, Sweden, this week. This city is home to Pharem Biotech, a company developing enzymes to break down drug residues contaminating wastewater. Mission: To remove drug residue from sewage water by developing enzymes that are modified to be 200 times more effective than natural enzymes. This technology could reduce the ecological and health […] August 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Aug 2019 Late-Stage Clinical Trial Troubles for Dry Eye Disease Drug A drug developed by the UK company Topivert Pharma has failed to reduce eyeball grittiness sensations in patients with dry eye disease in a phase II/III trial. The trial tested Topivert’s small molecule drug given as eyedrops to 202 patients suffering from dry eye disease, a condition where not enough tears are produced to lubricate […] August 7, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Aug 2019 ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment Two companies based in Lausanne, Switzerland — ADC Therapeutics and the genomics company SOPHiA Genetics — have signed a deal to identify patients most likely to respond to a blood cancer drug. ADC Therapeutics will send SOPHiA Genetics blood samples collected from an ongoing phase II trial. The trial is testing a treatment for patients […] August 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 5 Aug 2019 Phase II Promise for Inhaled Chronic Lung Disease Treatment A first-in-class inhaled drug developed by the UK biotech Verona Pharma improved lung function in a phase II trial treating the lung condition chronic obstructive pulmonary disease. The 37 patients in the trial had chronic obstructive pulmonary disease (COPD), a common lung condition that involves a tightening of the lung airways and breathlessness. Verona Pharma […] August 5, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2019 Oncolytic Virus for Liver Cancer Ruled Futile in Phase III A phase III trial testing an oncolytic virus treatment for liver cancer, developed by the French biotech Transgene, has been discontinued after interim analyses concluded that the treatment was unlikely to succeed. Originally expected to finish in 2020, the phase III trial tested the oncolytic virus treatment Pexa-Vec in patients with the liver cancer hepatocellular […] August 2, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 2 Aug 2019 This Biotech Uses Messenger RNA to Treat Lethal Lung Inflammation Based close to Berlin, Germany, the biotech startup Pantherna Therapeutics is developing a messenger RNA drug to treat a life-threatening lung condition that requires mechanical ventilation. Mission: To develop a messenger RNA (mRNA) drug to treat acute respiratory distress syndrome, an inflammatory lung reaction that kills up to half of patients with the condition. Acute […] August 2, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 1 Aug 2019 Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III Hopes of seeing an approved treatment for the inflammatory bowel condition pouchitis have been dashed as the UK company Atlantic Healthcare’s RNA drug has proved ineffective in a phase III trial. The trial tested Atlantic Healthcare’s RNA drug alicaforsen as a treatment for patients with pouchitis. Patients with this condition have their colon surgically replaced […] August 1, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2019 British Biotech Raises €11M to Market Personalized Medicine Test The UK biotech PredictImmune has raised €11M (£10M) in a Series B fundraising round to commercialize technology to predict the progress of inflammatory bowel disease in newly diagnosed patients. The funds will finance the global launch of PredictSURE IBD, a blood test that can identify patients with the most severe cases of inflammatory bowel disease, […] July 31, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2019 French Biotech’s Insulin Resistance Treatment Boosted by €67M Series A The French company Alizé Pharma III has raised a Series A round of €67M to push two peptide drugs into phase I, including a drug treating rare genetic conditions causing insulin resistance. The money will advance Alizé Pharma III’s two preclinical drugs into clinical trials, with phase I trials expected to begin in 2020. One […] July 31, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jul 2019 Belgian Biotech Raises €35M to Develop Eco-Friendly Pesticides The Belgium-based company AgroSavfe has raised a Series C round of €35M to develop an environmentally friendly crop pesticide inspired by llama antibodies. AgroSavfe will use the funds to develop and manufacture its lead protein fungicide on a commercial scale. The company aims to get approval from the US Environmental Protection Agency and launch the […] July 30, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jul 2019 €43M Series C to Launch UK Company’s Home Hemodialysis Kit Quanta Dialysis Technologies has raised €43.2M ($48M) to fund the commercial launch of a device that makes home hemodialysis more straightforward and economical for kidney failure patients. The UK-based Quanta will use the money to launch its technology in the UK later this year, and also apply for FDA approval. The technology previously obtained a […] July 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 26 Jul 2019 This Biotech Makes Food for Space Missions Using Bacteria Time to head to Helsinki, Finland, this week! We’re visiting Solar Foods, a biotech using bacteria to produce protein-rich flour out of carbon dioxide and water. Mission: To develop a protein-rich powder that can be made with little more than bacteria, electricity and water. This production method could be more efficient and sustainable than traditional […] July 26, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email